As the ability to clinically evaluate patients’ more individualized cellular phenotypes in critical illness continues to expand, HVEM+BTLA+ co-expression should be considered as a marker of risk for infection as well as a potential therapeutic target to modulate the immune response to critical illness, offering a novel means of preventing critical illness-related complications. The gene discussed is BTLA; the disease is infection.